Nov 9, 2017 8:30 am EST Nemus Bioscience Files Arbitration Petition Against Schneider Finance, LLC and SB Securities, Ltd. for Failure to Close $20 Million Financing and Failure to Honor Guarantee
Nov 6, 2017 8:30 am EST NEMUS Bioscience Announces Presentation of CBD-analogue Therapeutic Data Related to Neuropathic Pain (NB2111) and Ocular Diseases (NB2222) at Upcoming Scientific Meetings
Oct 13, 2017 8:00 am EDT NEMUS Bioscience Provides Further Update on Previously Announced $20 Million Schneider Financing
Aug 7, 2017 8:30 am EDT NEMUS Bioscience Announces Presentation of CBD-analogue (NB2222) Ocular Data at the AAPS 2017 Annual Meeting
Aug 2, 2017 8:30 am EDT Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference
Jul 17, 2017 8:30 am EDT NEMUS Bioscience Announces NB2222 Pain and Anti-Addiction Data Accepted for Presentation at Upcoming Society of Neuroscience Meeting
Jul 11, 2017 8:30 am EDT NEMUS Bioscience Provides Update on Previously Announced $20 Million Schneider Financing
Jun 22, 2017 5:30 am EDT Nemus Bioscience Announces NB1111 Data Presentation at the 27th Annual Symposium of the International Cannabinoid Research Society (ICRS)
May 17, 2017 8:30 am EDT Nemus Bioscience Reports Prodrug of Tetrahydrocannabinol (THC) Issued Patent Coverage in Canada and Hong Kong